Primary Recommendation

Quantum Pharma - Explosive growth trajectory

June 2015

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

A feature of new issues in the past couple of years has meant that the stockmarket now has a significant biotech/niche pharmaceutical sector. On SCSW, we’re not too keen on pure biotech as it can take 10-15 years from initial discovery to commercial exploitation, but we certainly have a liking for fledgling pharma businesses and have already recommended Clinigen (tipped at 196p, now 636p), Hutchinson China (tipped at 304p, now 1815p) and AMS (a more recent recommendation at 110p, now 148p). All three have profitable businesses, which generate significant amounts of cash.This month’s recommendation is County Durham–based Quantum Pharma, a major player in the market for “special” pharmaceuticals an ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Market Comment - June 2015

Redcentric - Strong visibility of earnings

Quantum Pharma - Gain since our February write up: 75% (October 2017)

Quantum Pharma - Bid from Clinigen (September 2017)

Quantum Pharma (June 2017)

Quantum Pharma - Considerably less flannel from new CEO (February 2017)

Quantum Pharma - Sweep of board and placing (November 2016)

Quantum Pharma (June 2016)

Quantum Pharma (March 2016)

Quantum Pharma - Five more products now approved (November 2015)

Quantum Pharma - Soon-to-be prospective PE of 9.9 (October 2015)

Quantum Pharma (September 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X